Citations

Clear

17 citation(s) found for "Schwenk, W Frederick".

Bone Age: A Handy Tool for Pediatric Providers
Creo, Ana L. , Schwenk, W. Frederick, Schwenk, W. Frederick

Mayo Clinic

Pediatrics | November 15, 2017 | Volume: 140 | Issue: 6 | Pages: No page available

10.1542/peds.2017-1486 | PMID 29141916 Get It

Pediatricians have relied on methods for determining skeletal maturation for >75 years. Bone age continues to be a valuable tool in assessing children’s health. New technology for bone age determination includes computer-automated readings and assessments obtained from alternative imaging modalities. In addition, new nonclinical bone age applications are evolving, particularly pertaining to immigration and children’s rights to asylum. Given the significant implications when bone ages are used in high-stake decisions, it is necessary to recognize recently described limitations in predicting accurate age in various ethnicities and diseases. Current methods of assessing skeletal maturation are derived from primarily white populations. In modern studies, researchers have explored the accuracy of bone age across various ethnicities in the United States. Researchers suggest there is evidence that indicates the bone ages obtained from current methods are less generalizable to children of other ethnicities, particularly children with African and certain Asian backgrounds. Many of the contemporary methods of bone age determination may be calibrated to individual populations and hold promise to perform better in a wider range of ethnicities, but more data are needed.
Effect of enteral vs. parenteral glucose delivery on initial splanchnic glucose uptake in nondiabetic humans
Shah, Pankaj, Basu, Rita , Basu, Ananda , Camilleri, Michael , Schwenk, W. Frederick, Rizza, Robert A., Vella, Adrian , Schwenk, W. Frederick

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | February 27, 2015 | Volume: 283 | Issue: 2 | Pages: E259-E266

10.1152/ajpendo.00178.2001 | PMID 12110530 Get It

To determine if enteral delivery of glucose influences splanchnic glucose metabolism, 10 subjects were studied when glucose was either infused into the duodenum at a rate of 22 μmol · kg −1 · min −1 and supplemental glucose given intravenously or when all glucose was infused intravenously while saline was infused intraduodenally. Hormone secretion was inhibited with somatostatin, and glucose (∼8.5 mmol/l) and insulin (∼450 pmol/l) were maintained at constant but elevated levels. Intravenously infused [6,6- 2 H 2 ]glucose was used to trace the systemic appearance of intraduodenally infused [3- 3 H]glucose, whereas UDP-glucose flux (an index of hepatic glycogen synthesis) was measured using the acetaminophen glucuronide method. Despite differences in the route of glucose delivery, glucose production (3.5 ± 1.0 vs. 3.3 ± 1.0 μmol · kg −1 · min −1 ) and glucose disappearance (78.9 ± 5.7 vs. 85.0 ± 7.2 μmol · kg −1 · min −1 ) were comparable on intraduodenal and intravenous study days. Initial splanchnic glucose extraction (17.5 ± 4.4 vs. 14.5 ± 2.9%) and hepatic UDP-glucose flux (9.0 ± 2.0 vs. 10.3 ± 1.5 μmol · kg −1 · min −1 ) also did not differ on the intraduodenal and intravenous study days. These data argue against the existence of an “enteric” factor that directly (i.e., independently of circulating hormone concentrations) enhances splanchnic glucose uptake or hepatic glycogen synthesis in nondiabetic humans.
Care of the Child with Diabetes
Schwenk, W Frederick, Schwenk, W Frederick

Mayo Clinic

Diabetes Care | December 11, 2014 | Volume: 10 | Issue: 4 | Pages: 528-528

10.2337/diacare.10.4.528b Get It

Pediatric Endocrine Surgery: A 20-Year Experience at the Mayo Clinic
Kundel, Anna, Thompson, Geoffrey B. , Richards, Melanie L., Qiu, Lizhen, Cai, Yefeng , Schwenk, Frederick W., Lteif, Aida, Pittock, Siobhán T. , Kumar, Seema , Tebben, Peter J. , Grant, Clive S., Hay, Ian , Tebben, Peter

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 12, 2013 | Volume: 99 | Issue: 2 | Pages: 399-406

10.1210/jc.2013-2617 | PMID 24423286 Get It

Assessment of Hepatic Sensitivity to Glucagon in NIDDM: Use as a Tool to Estimate the Contribution of the Indirect Pathway to Nocturnal Glycogen Synthesis
Nielsen, Michael Festersen , Wise, S, Schwenk, W Frederick, Basil, Ananda, Rizza, Robert A., Dinneen, Seán F. , Schwenk, W Frederick

Mayo Clinic

Diabetes | September 19, 2013 | Volume: 46 | Issue: 12 | Pages: 2007-2016

10.2337/diab.46.12.2007 | PMID 9392488 Get It

NIDDM is associated with excessive rates of endogenous glucose production in both the postabsorptive and postprandial states. To determine whether this is due to an intrinsic increase in hepatic sensitivity to glucagon, 9 NIDDM and 10 nondiabetic subjects were studied on three occasions. On each occasion, glycogen was labeled the evening before the study with subjects ingesting meals containing [6-3H]galactose. Beginning at 6:00 A.M. on the following morning, somatostatin was infused to inhibit endogenous hormone secretion. Insulin concentrations were maintained constant at basal levels (defined as that necessary to keep glucose at ∼5 mmol/l) in each individual. On one occasion, glucagon was infused at a rate of 0.65 ng ∼ kg−1 · min−1 throughout the experiment, resulting in glucagon concentrations of ∼130 pg/ml and a slow but comparable fall in endogenous glucose production with time in both groups. On the other two occasions, the glucagon infusion was increased at 10:00 A.M. to either 1.5 or 3.0 ng · kg−1 · min−1, resulting in an increase in glucagon concentrations to ∼180 and 310 pg/ml, respectively. The increment in endogenous glucose production (i.e., area above basal) did not differ in diabetic and nondiabetic subjects during either the 1.5 ng · kg−1 · min−1 (0.75 ± 0.055 vs. 0.78 ± 0.048 mmol/kg) or 3.0 ng · kg−1 · min−1 (1.06 ± 0.066 vs. 1.10 ± 0.073 mmol/kg) glucagon infusions. In contrast, the amount of [6-3H]glucose released from glycogen was lower (P < 0.05) in the diabetic than nondiabetic subjects during both glucagon infusions. The specific activity of glycogen, calculated as the integrated release of [6-3H]glucose divided by the integrated release of unlabeled glucose, was lower (P < 0.05) in diabetic subjects than in nondiabetic subjects during both the 1.5 ng · kg−1 · min−1 (19.0 ± 3.9 vs. 41.4 ± 5.7 dpmμmol) and 3.0 ng · kg−1 · min−1 (19.1 ± 3.1 vs. 36.5 ± 7.2 dpm/μmol) glucagon infusions, implying that a greater portion of the glucose released from glycogen was derived from the indirect pathway. We concluded that although NIDDM is not associated with an intrinsic alteration in hepatic sensitivity to glucagon, it does alter the relative contributions of the direct and indirect pathways to nocturnal glycogen synthesis.
Hepatic and Extrahepatic Responses to Insulin in NIDDM and Nondiabetic Humans: Assessment in Absence of Artifact Introduced by Tritiated Nonglucose Contaminants
Butler, Peter C. , Kryshak, Edward J, Schwenk, W Frederick, Haymond, Morey W. , Rizza, Robert A., Schwenk, W Frederick

Mayo Clinic

Diabetes | September 19, 2013 | Volume: 39 | Issue: 2 | Pages: 217-225

10.2337/diab.39.2.217 | PMID 2227130 Get It

It is well established that patients with non-insulindependent diabetes mellitus (NIDDM) are resistant to insulin. However, the contribution of hepatic and extrahepatic tissues to insulin resistance remains controversial. The uncertainty may be at least in part due to errors introduced by the unknowing use in previous studies of impure isotopes to measure glucose turnover. To determine hepatic and extrahepatic responses to insulin in the absence of these errors, steady-state glucose turnover was measured simultaneously with [6-3H]- and [6-14C]glucose during sequential 5- and 4-h infusions of insulin at rates of 0.4 and 10 mil · kg−1 · min−1 in diabetic and nondiabetic subjects. At low insulin concentrations, [6-3H]- and [6-14C]glucose gave similar estimates of glucose turnover. Hepatic glucose release was equal to but not below zero in the nondiabetic subjects, but persistent glucose release (P < 0.001) and decreased glucose uptake (P < 0.001) was observed in the diabetic patients. At high insulin concentrations, both isotopes underestimated glucose turnover during the 1st h after initiation of the highdose insulin infusion. More time (P < 0.05) was required to reachieve steady state in NIDDM than nondiabetic subjects. At steady state, [6-3H] but not [6-14C]glucose systematically underestimated (P < 0.05) glucose turnover in both groups due to the presence of a tritiated nonglucose contaminant. The percentage of radioactivity in plasma due to tritiated contaminants was linearly related to turnover. When plasma [6-3H]glucose specific activity was corrected for the presence of the contaminant in each subject, both [6-3H]- and [6-14C]glucose indicated that diabetic patients had hepatic and extrahepatic insulin resistance. We conclude that in these experiments, although the presence of a low percentage of tritiated nonglucose contaminant in the tracer may alter estimates of the severity of hepatic and extrahepatic insulin resistance in patients with NIDDM, it does not obscure their presence
Effects of Acute Metabolic Acidosis and Alkalosis on Leucine Metabolism in Conscious Dogs
Rodríguez, Nancy, Miles, John M, Schwenk, W Frederick, Haymond, Morey W. , Miles, John M, Schwenk, W Frederick

Mayo Clinic

Diabetes | September 19, 2013 | Volume: 38 | Issue: 7 | Pages: 847-853

10.2337/diab.38.7.847 | PMID 2544471 Get It

To determine the effects of acute metabolic acidosis and alkalosis on leucine metabolism in vivo, mongrel dogs were infused with [1-14C] leucine for 8 h, along with NaCI, HCI, or NaHCO3 over the last 4 h. Arterial pH did not change from the basal value during NaCI infusion but decreased (P <.01) and increased (P <.01) during HCI and NaHCO3 infusions, respectively. Total leucine carbon entry did not change from the basal value during saline infusion but increased (P <.01) with acidosis and decreased (P <.05) with alkalosis. Compared with saline controls, acidosis increased (P <.01) leucine oxidation, whereas alkalosis decreased (P <.01) leucine oxidation. During acidosis, total plasma essential and nonessential amino acid concentrations increased (P <.05), whereas during alkalosis, total plasma essential and nonessential amino acid concentrations decreased (P <.05). These studies suggest that acute alterations in arterial pH may affect the regulation of protein metabolism in vivo and must be considered in the interpretation of results from experiments in which alterations of acid-base homeostasis may have occurred.
Contribution of Insulin Resistance to Catabolic Effect of Prednisone on Leucine Metabolism in Humans
Zimmerman, T, Horber, Fritz , Rodríguez, Nancy, Schwenk, W Frederick, Haymond, Morey W. , Schwenk, W Frederick

Mayo Clinic

Diabetes | September 19, 2013 | Volume: 38 | Issue: 10 | Pages: 1238-1244

10.2337/diab.38.10.1238 | PMID 2571541 Get It

To determine the role insulin resistance may play in the catabolic effect of high-dose prednisone therapy, healthy volunteers were studied on four occasions with the hormone-clamp technique at two insulin infusion rates. Subjects were studied after 5 days of prednisone (60 mg/day) or no steroid treatment and were infused with somatostatin, glucagon, growth hormone, [3H]glucose, [14C]leucine, and insulin (0.1 or 0.2 mil · kg1 · min1). At each rate of insulin infusion, the rate of leucine oxidation was increased (P < .001) after steroid treatment. Leucine flux, an indicator of whole-body proteolysis, was similar in the presence or absence of steroid treatment (2.26 ± 0.08 vs. 2.13 ± 0.04 μmol · kg1 · min1 respectively) at the lower rate of insulin infusion but was higher during steroid treatment (2.18 ± 0.06 vs. 1.84 ± 0.13 μmol · kg1 · min1) at the 0.2-mU · kg1 · min1 insulin infusion. Steroid pretreatment had no significant effect on the nonoxidative rates of leucine disappearance. These data provide strong evidence that the protein wasting associated with glucocorticosteroid therapy is in part the result of steroid-induced resistance to the antiproteolytic effect of insulin and an increase in the oxidation (and thus wasting) of one essential amino acid, leucine.
Underestimation of Glucose Turnover Measured With [6-3H]- and [6,6-2 H2]- but not [6-14C]glucose During Hyperinsulinemia in Humans
McMahon, M. Molly , Schwenk, W Frederick, Haymond, Morey W. , Rizza, Robert A., Schwenk, W Frederick

Mayo Clinic

Diabetes | September 19, 2013 | Volume: 38 | Issue: 1 | Pages: 97-107

10.2337/diab.38.1.97 | PMID 2642438 Get It

Recent studies indicate that hydrogen-labeled glucose tracers underestimate glucose turnover in humans under conditions of high flux. The cause of this underestimation is unknown. To determine whether the error is time-, pool-, model-, or insulin-dependent, glucose turnover was measured simultaneously with [6-3H]-, [6,6-2H2]-, and [6-14C]glucose during a 7-h infusion of either insulin (1 mU · kg−1 · min−1) or saline. During the insulin infusion, steady-state glucose turnover measured with both [6-3H]glucose (8.0 ± 0.5 mg · kg−1 · min−1) and [6,6-2H2]glucose (7.6 ± 0.5 mg kg−1 min−1) was lower (P < .01) than either the glucose infusion rate required to maintain euglycemia (9.8 ± 0.6 mg · kg−1 · min−1) or glucose turnover determined with [6-14 C]glucose and corrected for Cori cycle activity (9.8 ± 0.7 mg · kg−1 · min1). Consequently “negative” glucose production rates (P <.01) were obtained with either [6-3 H]- or [6,6-2 H2]-but not [6-14 C]glucose. The difference between turnover estimated with [6-3 H]glucose and actual glucose disposal (or 14C glucose flux) did not decrease with time and was not dependent on duration of isotope infusion. During saline infusion, estimates of glucose turnover were similar regardless of the glucose tracer used. High-performance liquid chromatography of the radioactive glucose tracer and plasma revealed the presence of a tritiated nonglucose contaminant. Although the contaminant represented only 1.5% of the radioactivity in the [6-3H]glucose infusate, its clearance was 10-fold less (P <.001) than that of [6-3H]glucose. This resulted in accumulation in plasma, with the contaminant accounting for 16.6 ± 2.09 and 10.8 ± 0.9% of what customarily is assumed to be plasma glucose radioactivity during the insulin or saline infusion, respectively (P < .01). When corrected for the presence of the contaminant, glucose turnover determined with [6-3H]glucose during insulin infusion (9.5 ± 0.6 mg · kg−1 · min−1) no longer differed from either the glucose infusion rate or that determined with [6-14C]glucose. Therefore, the underestimation of glucose turnover during insulin infusion and negative glucose production rates observed with traditional methods to analyze plasma radioactivity and commercially available tracers is the result of an artifactual increase in [6-3H]glucose specific activity. The etiology of the underestimation of glucose turnover with [6,6-2H2]glucose remains to be determined.
Decreased Uptake of Glucose by Human Forearm During Infusion of Leucine, Isoleucine, or Threonine
Schwenk, W Frederick, Haymond, Morey W. , Schwenk, W Frederick

Mayo Clinic

Diabetes | September 19, 2013 | Volume: 36 | Issue: 2 | Pages: 199-204

10.2337/diab.36.2.199 | PMID 3100368 Get It

Competition between glucose and free fatty acids as metabolic fuels is supported by both in vitro and in vivo data, but whether amino acids can also compete with glucose as a source of energy in vivo remains to be established. To determine the effect of increased availability of an amino acid on whole-body glucose flux and glucose carbon uptake by the human forearm, five groups of overnight-fasted normal subjects were infused with either saline, leucine (at 0.5 or 1.0μmol · kg−1 · min−1), isoleucine (0.5 μmol · kg−1 · min−1), or threonine (0.5 μmol · kg−1 · min−1). Plasma glucose concentrations and glucose flux decreased similarly in all groups. No significant changes in forearm output of leucine carbon, isoleucine carbon, or threonine were seen during saline infusion. In contrast, during leucine infusion there was a dose-dependent increase (r = .86, P < .001) in leucine carbon uptake with increased arterial leucine and a-ketoisocaproate concentrations. During infusions of isoleucine and threonine, increases (P < .05) in isoleucine carbon uptake and threonine uptake, respectively, were observed. Glucose uptake by forearm tissues did not change during the saline infusion, but it decreased (P < .05) in all four groups receiving an amino acid infusion. Changes in leucine carbon uptake were strongly correlated (r = −.76, P < .001) with changes in glucose uptake. Therefore, amino acids affect glucose uptake in human forearm tissue and presumably compete as oxidative fuels.